Skip to Main Content

Paper Details

Canagliflozin and cardiovascular outcomes in Type 2 diabetes.
Future Cardiol
1
2021
Author NameAffiliation
Fatima RodriguezDivision of Cardiovascular Medicine & Cardiovascular Institute, Stanford University School of Medicine
Kenneth W MahaffeyDivision of Cardiovascular Medicine & Cardiovascular Institute, Stanford University School of Medicine
Kenneth W MahaffeyStanford Center for Clinical Research
  • 1 - 3

Datasets

Release 1.2